LDLR and atherosclerosis: SRT3025, a SIRT1 activator, inhibits atherosclerosis in ApoE-/- mice through reducing hepatic PCSK9 expression and increasing LDLR expression.441 Human and mouse plaque VSMCs exhibit reduced SIRT6 expression.